Icon to acquire Aptiv Solutions
pharmafile | March 31, 2014 | News story | Manufacturing and Production | Aptiv Solutions, ICON, addplan, manufacturing
Icon has acquired US clinical trial specialists Aptiv Solutions for $143.5 million as it looks to expand its footprint in adaptive and medical device studies.
Headquartered in Reston Virginia and with operations in 16 countries, Aptiv Solutions specialises in the design and execution of adaptive clinical trials for pharma and biotech firms.
The company’s offering is centred on its Addplan software that supports the design, simulation and analysis of adaptive trials. Icon notes that this is used by a number of drug regulators across the world, as well as over 50 top pharma and medical device companies.
Aptiv Solutions also owns Niphix, an oncology-focussed contract research organisation serving both Japanese and international customers.
Icon says that this unit will be combined with its current operations in Tokyo and Osaka, thereby expanding its offerings in Japan.
In addition, Icon adds that Aptiv Solutions has experience in the management of medical device trials, “leveraging its adaptive capabilities and regulatory expertise to speed up the development of a wide-range of medical devices”.
Commenting on the acquisition, Dr Nuala Murphy, president of Icon’s clinical research services, says: “Icon’s market-leading innovation is helping our customers to reduce the time and cost of drug development. We are achieving this through the combination of our industry expertise and enabling technologies such as Iconik and Firecrest.
“Aptiv Solutions’ adaptive trial capabilities will further differentiate and enhance our services to help our customers identify the most promising drug candidates earlier. Their presence in Japan will also broaden our existing capabilities in this market.”
“Icon is the perfect fit for Aptiv Solutions” says Pat Donnelly, chairman and chief executive of Aptiv Solutions. “Our unique technology and expertise in integrated design and execution of adaptive trials, our strength in medical device development and our strong position in oncology in Japan are key areas of differentiation.”
He adds: “Icon’s excellence in execution, geographic reach, and shared focus on innovation will position the combined entity as the go-to service provider for design and execution of adaptive trials for drug, diagnostic and medical device companies in a fast-growing market.”
Ben Adams
Related Content
Ardena announces €20m expansion following first GMP approval
Ardena has announced that it has received Good Manufacturing Practice (GMP) approval from the Dutch …
Lonza to acquire biologics site in Vacaville, US from Roche for $1.2bn
Lonza has announced that it has signed an agreement to acquire the Genentech large-scale biologics …
AbbVie invests $223m in Singapore manufacturing site
AbbVie has announced that it has invested $223m in an expansion to its Singapore manufacturing …
